IL6 and COVID-19: The use of IFN-α2-β in combination with Arbidol significantly reduced the virus persistence in the upper respiratory tract and shortened the presence of the inflammatory markers IL-6 and CRP in adults hospitalized with COVID-19 [93] at the same time.